Parallel Bio
PrivateLast Round
Series A
Jun 12, 2025
Total Funding Raised
$25.43M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Parallel Bio is a biotechnology company that pioneers human-first drug discovery by combining immune organoids with artificial intelligence to replicate the human immune system for testing immunotherapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Parallel Bio Comparables
Compare Parallel Bio with similar companies based on industry and business-model similarity.
Parallel Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 12, 2025 | ||||
| Seed | Dec 20, 2022 | ||||
| Seed | Sep 1, 2021 |
Parallel Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Refactor Capital | Seed |
| Atypical | Series A |
| Amplo | Series A |
| Metaplanet Holdings | Series A |
| Breakout Ventures | Seed |
| Humba Ventures | Series A |
| Y Combinator | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Data supports partner's FDA filing for Phase 1 trial.
- Mar 1, 2026
Executed 10 pharma contracts with strong year-over-year revenue growth.
Recent news
Latest coverage and updates
- expands_offices_toJun 16, 2026
Parallel expanded offices to San Francisco, California, United States, Northern America, Americas on Jun 16th '26.
Parallel Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Parallel Bio's valuation, stock price, and market status.
Is Parallel Bio a public or private company?
Parallel Bio is a private company.
What is the current stock price of Parallel Bio?
Parallel Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Parallel Bio worth (valuation)?
Valuation information for Parallel Bio is not publicly available.
Can I buy Parallel Bio stock?
Parallel Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Parallel Bio's last funding round?
Parallel Bio's most recent funding round was Series A on June 12, 2025.
Who are the main investors in Parallel Bio?
Key investors in Parallel Bio include Refactor Capital, Y Combinator, AIX Ventures.
Will Parallel Bio IPO soon?
No public IPO plans have been announced for Parallel Bio.
How can I track Parallel Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Parallel Bio's secondary market activity and sign up for updates.